M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells
Cinzia Borghese,Naike Casagrande,Eliana Pivetta,Alfonso Colombatti,Mariarosaria Boccellino,Mariarosaria Boccellino,Evzen Amler,Evzen Amler,Nicola Normanno,Michele Caraglia,Michele Caraglia,Giuseppe De Rosa,Donatella Aldinucci +12 more
TL;DR: It is demonstrated that NZ is capable to inhibit the cross talk between MSCs and PCa, providing a novel insight to explain the powerful anticancer activity of NZ on PCa.
Journal ArticleDOI
Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells.
Carla Esposito,Monica Marra,Gaia Giuberti,Anna Maria D'Alessandro,Raffaele Porta,Anna Cozzolino,Michele Caraglia,Alberto Abbruzzese +7 more
TL;DR: It is demonstrated for the first time that tTG is ubiquitinated and degraded by a proteasome-dependent pathway and IFNalpha can, at least in part, induce apoptosis through the modulation of this pathway.
Journal ArticleDOI
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Pierpaolo Correale,Salvatora Tindara Miano,Cinzia Remondo,Cristina Migali,Maria Saveria Rotundo,Paolo Macrì,Pierosandro Tagliaferri,Michele Caraglia,Giuseppe Gotti,Guido Francini +9 more
TL;DR: The biweekly GD regimen is a safe and active second-line treatment in NSCLC and addition of immune-adjuvant cytokines' may enhance the activity of this therapeutic combination.
Journal ArticleDOI
Endocrine disruptors and female cancer: Informing the patients (Review)
Lino Del Pup,Alberto Mantovani,Amalia Luce,Carla Cavaliere,Gaetano Facchini,Raffaele Di Francia,Michele Caraglia,Massimiliano Berretta +7 more
TL;DR: The carcinogenic effects of endocrine disruptors on female cancer types is plausible although additional studies are needed to clarify their mechanisms and entities, and ways to reduce ED exposure are suggested.
Journal ArticleDOI
Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection
Sisto Perdonà,Giuseppe Di Lorenzo,Riccardo Autorino,Carlo Buonerba,Marco De Sio,Sergio Venanzio Setola,Roberta Fusco,Francesco Michele Ronza,Michele Caraglia,Matteo Ferro,Antonella Petrillo +10 more
TL;DR: This study confirms the potential usefulness of MRI for the diagnosis of CaP in patients with low PSA levels but the positive predictive value obtained was unacceptably low due to the high number of false positives recorded.